TickerTalks
Browse all tickers →
TickerTalks›$CAH
CACAH

Cardinal Health, Inc.

$CAH·$56B·Medical - Distribution·Healthcare
$234.55-0.2%1Y+56.9%
Mentions · last 7 days
2026-08-20: 17 posts2026-08-21: 6 posts2026-08-22: 6 posts66+8%
Price updated 2d ago·X counts updated 8d ago
CACAH
$CAHCardinal Health, Inc.
$234.55-0.25%66 posts+8%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $CAH, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersCooling offAI verdict · as of 2026-08-26

Catching its breath after a run — could pick back up or fade from here.

Cardinal Health is up 63% t12m — CFO Hollar just sold $10.5M and officer Mason $8.3M on the same day, real distribution at the highs.

Cardinal Health is the pharmaceutical distribution and medical-products company that has quietly become a compounder as generic-pricing pressure eased. The stock is up 63% t12m but the tape is cooling as officers take serious profits.

  • The Q2 print was strong: EPS $2.91 vs sell-side $2.42 (a 20% beat) with revenue $60.9B — the last two prints delivered EPS beats of 20% and 14%, and FY27 sell-side EPS at $9.50+ implies ~25x forward at $238, elevated but reasonable for a scale-driven distribution business with earnings-quality improvement.
  • The insider tape is unusually loud and coordinated: CFO Jason Hollar sold $10.5M on Aug 20, officer Stephen Mason sold $8.3M the same day, plus officer Scherer $546K — combined $19M+ in a single day at ~$236 is exceptional single-name distribution size, and it's the leading indicator of the cooling trajectory.
  • The tape has cooled but not broken: at 82% of the 52-week range, 2% above the 50-day and 11% above the 200-day on 0.66x normal volume with beta 0.52 — a defensive-beta distribution name pulling back on light volume after a big run is orderly rotation; the $19M insider dispositions are what has capped the tape near the highs.

The path if this works is the Oct 29 Q1 print delivering another clean beat plus concrete generic-pricing commentary, taking the tape past $260. What breaks it is another Hollar/Mason-scale open-market sale or a fresh generic-pricing shock — the operating story is intact but the coordinated $19M CFO+officer selling on a single day is a genuine cautionary signal.

Differs from X sentimentThe bullish X chatter is about a Moontropica CAH crypto token (community pumping, $45 targets, patient wait for a boom), not Cardinal Health the pharma distributor — cashtag collision — so the X sentiment isn't a signal for the equity at all; the actual data (Q2 20% beat, $19M coordinated insider sales) is not what the crypto sample discusses.

What to watch: Oct 29 Q1 print (sell-side EPS $2.91) — a clean beat plus concrete generic-pricing commentary extends the tape past $260; another Hollar/Mason-scale open-market sale in the next 8-K or a fresh generic-pricing shock breaks the cooling back to $190.

On the calendar: 2026-10-29 — Q1 earnings

cashtag confusion

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Neutral sentiment5 posts analyzed · as of 2026-08-26

$CAH chatter is entirely about the MoonTropica crypto token — long-term bull-run price targets, patience-through-70%-dump rhetoric, and cross-asset baskets. There is no discussion of any US-listed equity of the same ticker (Cardinal Health) in this window.

Read the AI verdict + X sentiment for $CAH

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Healthcare distributor and services company supplying pharmaceuticals, medical products, and specialty logistics to US hospitals and providers.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Distribution sits in its cycle right now — and what that implies for $CAH.

Medical - Distribution · Healthcare

Top industry ETF

$XLVHealth Care Select Sector SPDR
+4.7%YTD
+25.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
36.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
11.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
7.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-55.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
3.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-3.5Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 11, 2026$2.91$2.42+20.2%
Q1 2026Apr 30, 2026$3.17$2.79+13.6%
Q4 2025Feb 5, 2026$2.63$2.34+12.4%
Q3 2025Oct 30, 2025$2.55$2.18+17.0%
Next earningsThu, Oct 29·consensus EPS $2.92

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q3 FY26$60.9B+11.0%4.1%0.8%$1.69$1.7B
Q2 FY26$65.4B+18.4%3.4%1.1%$1.98$555.0M
Q1 FY26$64.0B+22.4%3.6%1.0%$1.89$865.0M
Q4 FY25$60.2B+0.8%3.7%0.7%$1.00$1.3B

Forward consensus

4-year forecast · up to 13 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$275.6B$270.7B – $281.2B$12.08$11.70 – $12.4512
FY27$297.8B$276.4B – $309.2B$13.59$10.53 – $15.5813
FY28$320.4B$315.7B – $329.9B$15.44$13.32 – $17.135
FY29$339.0B$326.5B – $348.9B$17.71$16.87 – $18.382

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.79%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+0.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+9.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 233.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.525-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 19Mary C. SchererChief Accounting Officer2.3K sh$546KSellAug 19Jason M. HollarCEO44.5K sh$10.5MSellAug 18Jason M. HollarCEO80.0K sh$18.9MSellAug 18Stephen M MasonCEO35.0K sh$8.3MSellAug 18Deborah WeitzmanCEO7.4K sh$1.7MSellAug 18Aaron E AltCFO42.0K sh$9.9MSellAug 18Jessica L MayerChief Legal/Compliance Officer29.4K sh$7.0MSellAug 18Michelle D. GreeneChief Information Officer11.7K sh$2.7M
+ 25 other (17 awards · 8 inkinds) in window

See when $CAH insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDAug 118-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

Cardinal Health, Inc. (CAH) filed an 8-K on August 11, 2026, disclosing its financial results for the fourth quarter and full fiscal year ended June 30, 2026 (Item 2.02). The company's CEO and CFO discussed results and provided a fiscal year 2027 outlook on a webcast held at 8:30 a.m. Eastern the same day, with slide materials available on the investor relations page. Full financial details — including revenue, earnings per share, and segment performance — are contained in the attached Exhibit 99.1 press release rather than the 8-K body. As a major pharmaceutical distribution and healthcare solutions company processing hundreds of billions in drug volume annually, Cardinal Health's fiscal year-end results and forward guidance are closely watched barometers of healthcare supply chain economics.

8-KAgreement terminatedAug 118-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.03: Material debt obligation
AI summary

Cardinal Health, Inc. (CAH) entered into a new $4.0 billion unsecured revolving credit facility on August 7, 2026, replacing its existing 364-day revolving credit facility, five-year revolving credit facility, and receivables sale facility program. Wells Fargo serves as Administrative Agent, with BofA, Goldman Sachs, JPMorgan, Barclays, Deutsche Bank, HSBC, PNC, and Bank of Nova Scotia as co-arrangers or documentation agents; the facility runs through August 7, 2031, with up to two one-year extension options. The agreement contains a single financial covenant — a maximum Consolidated Net Leverage Ratio of 4.00x — and will be used for general corporate purposes. For investors, consolidating multiple credit facilities into one larger, longer-dated revolver improves Cardinal Health's liquidity flexibility and simplifies its debt structure as it manages cash flows across its pharmaceutical and specialty businesses.

8-KOfficer or director changeAug 58-K — Item 5.02: Officer or director change
AI summary

Cardinal Health, Inc. (CAH), the Dublin, Ohio healthcare distribution company, filed an 8-K disclosing the appointment of Anita Zielinski as Chief Accounting Officer, effective November 5, 2026. Zielinski, 52, joins from Baxter International where she served as interim CFO and Senior VP/Chief Accounting Officer, and previously spent seven years at Sysco including as SVP/CFO of US Foodservice Operations and as SVP/Chief Accounting Officer. She will join as Senior VP Finance on September 16, 2026, with Mary Scherer continuing as CAO through the November 5 transition date. Compensation includes base salary, annual MIP bonus, long-term equity awards, and a sign-on cash bonus to offset forfeited compensation from her prior employer.

8-KPress release / Reg FDApr 308-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
8-KOfficer or director changeMar 238-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
8-KOfficer or director changeMar 58-K — Item 5.02: Officer or director change
+ 9 other (4 13Gs · 2 11-Ks · 1 10-K · 1 SD) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Cardinal Health (CAH) is a Top-Ranked Momentum Stock: Should You Buy?zacks.com·2d agoCardinal Health, Inc. $CAH Shares Bought by Algert Global LLCdefenseworld.net·3d agoReasons to Retain Cardinal Health Stock in Your Portfolio for Nowzacks.com·6d agoWhat to Know About the Latest Sale From Cardinal Health's Chief Accounting Officerfool.com·7d agoCardinal Health's CFO Moved $9.9 Million of Stock. Here's What Long-Term Investors Should Knowfool.com·7d ago
Voices on X · last 7 days

No standout posts about $CAH on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport